



Policy code	CPG_TO_CCB_0722
Date	July, 2022
Purpose	To ensure a consistent approach to the management of calcium channel blocker poisoning.
Scope	Applies to Queensland Ambulance Service (QAS) clinical staff.
Health care setting	Pre-hospital assessment and treatment.
Population	Applies to all ages unless stated otherwise.
Source of funding	Internal – 100%
Author	Clinical Quality & Patient Safety Unit, QAS
Review date	July, 2025
Information security	UNCLASSIFIED – Queensland Government Information Security Classification Framework.
URL	https://ambulance.qld.gov.au/clinical.html

While the QAS has attempted to contact all copyright owners, this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome. Please forward to: Clinical.Guidelines@ambulance.qld.gov.au

Disclaimer

The Digital Clinical Practice Manual is expressly intended for use by appropriately qualified QAS clinicians when performing duties and delivering ambulance services for, and on behalf of, the QAS.

The QAS disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this manual, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.

© State of Queensland (Queensland Ambulance Service) 2022.



This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International License

You are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute the State of Queensland, Queensland Ambulance Service and comply with the licence terms. If you alter the work, you may not share or distribute the modified work. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.o/deed.en

For copyright permissions beyond the scope of this license please contact: Clinical.Guidelines@ambulance.qld.gov.au

Calcium channel blocker

July, 2022

Calcium channel blockers (CCBs) are commonly prescribed medications used in the treatment of hypertension, angina pectoris and cardiac arrhythmia.[1] In overdose they can cause severe cardiovascular toxicity.

Examples:

- Verapamil
- Diltiazem
- **Amlodipine**
- Nifedipine
- Felodipine
- Lercanidipine

Most CCBs in therapeutic doses act to decrease blood pressure through vasodilation. In overdose this can lead to hypotension and vasodilatory shock.

Verapamil and diltiazem are particularly toxic as they also act on calcium channels in the heart to slow the heart rate and decrease myocardial contractility. In overdose they can cause bradycardia and cardiogenic shock.

Many CCBs are available as slow release preparations. Therefore, there can be a delay of many hours from time of ingestion before the onset of toxicity.

Calcium can ameliorate toxicity and is part of the treatment approach to severe poisoning. [2]



Cardiovascular effects

- Bradycardia
- Heart block
- Hypotension
- Cardiogenic shock

Systemic effects

- Seizures
- Coma
- Hyperglycaemia
- Metabolic acidosis



- CCB toxicity is potentially life-threatening, particularly if verapamil or diltiazem is taken which are more cardio selective.
- Older persons and those with underlying cardiovascular disease are more at risk of severe toxicity.
- Co-ingestion of other cardiac medication such as ACE inhibitors, beta blockers or digoxin can cause severe toxicity.[3,4]



